Probi´s Annual General Meeting 2014

On Probi´s Annual General Meeting on 29 April, 2014, the following was resolved:

  · The Annual General Meeting approved the Annual Report and the Boards
proposal for a dividend for the financial year 2013 corresponding to 0.75 SEK
per share.The record date was set for May 5, 2014.
  · The Annual General Meeting discharged the Board and the CEO from liability
for the financial year 2013.
  · The board shall consist of seven members without any deputies. Reelected
members were Benedicte Fossum, Mats Lidgard, Per Lundin, Declan McFadden, Jan
Nilsson and Eva Redhe Ridderstad. Newly elected was Jörn Andreas. Per Lundin was
reelected as Chairman of the Board. All in accordance with the nomination
commitees proposal.
  · The board fee was decided to a total of 1,200,000 SEK, whereof 300,000 SEK
to the chairman and 150,000 SEK to each of the other members.
  · Re-election of the registered public accounting firm Deloitte AB, and Per
-Arne Pettersson as principal auditor.
  · The board´s proposal regarding guidelines for renumeration of senior
executives was approved.
  · The Probi nomination committee shall consist of three shareholder
representatives and the Annual General Meeting selected Heinz-Jürgen Bertram
(Symrise), Jimmy Bengtsson (Skandia Liv) and Bengt Jeppsson (Professor, Surgical
Faculty, Lund University).

The CEO´s presentation will be available on www.probi.se.

The information is such that Probi AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e
-mail: peter.nahlstedt@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded biotechnology company that develops
effective and well-documented probiotics. Through its research, Probi has
created a strong product portfolio in the gastrointestinal health and immune
system areas. The products are available to consumers in more than 30 countries
worldwide. The customers are leading food, health-product and pharmaceutical
companies in the Functional Food and Consumer Healthcare segments. Probi had
sales of MSEK 102 in 2013. The Probi share is listed on NASDAQ OMX Stockholm,
Small-cap. Probi has approximately 3,500 shareholders. Read more on
www.probi.se.